TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07412288: First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

Sponsor: Kymera Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 96 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07412288 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07412288 Rescue Dossier →